北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 基础医学院  > 细胞生物学系  > 期刊论文
学科主题: 基础医学
题名:
A Minority Subpopulation of CD133+/EGFRvIII+/EGFR- Cells Acquires Stemness and Contributes to Gefitinib Resistance
作者: Liu, Xu-Jie1; Wu, Wen-Tao1; Wu, Wei-Hua1; Yin, Feng2; Ma, Si-Hai3; Qin, Jia-Zhen4; Liu, Xiu-Xiu1; Liu, Yi-Nan1; Zhang, Xiao-Yan1; Li, Peng1; Han, Shuo1; Liu, Kai-Yu5; Zhang, Jin-Ming6; He, Qi-Hua7; Shen, Li1
关键词: CD133 ; EGFRvIII ; Gefitinib resistance ; Stemness
刊名: CNS NEUROSCIENCE & THERAPEUTICS
发表日期: 2013-07-01
DOI: 10.1111/cns.12092
卷: 19, 期:7, 页:494-502
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Neurosciences ; Pharmacology & Pharmacy
研究领域[WOS]: Neurosciences & Neurology ; Pharmacology & Pharmacy
关键词[WOS]: EPIDERMAL-GROWTH-FACTOR ; FACTOR RECEPTOR GENE ; CONFERS ENHANCED TUMORIGENICITY ; TYROSINE KINASE INHIBITOR ; TUMOR-INITIATING CELLS ; HUMAN-BRAIN TUMORS ; GLIOBLASTOMA-MULTIFORME ; ZD1839 IRESSA ; BREAST-CANCER ; HUMAN GLIOMAS
英文摘要:

Aims To study the contribution of epidermal growth factor receptor variant III (EGFRvIII) to glioblastoma multiforme (GBM) stemness and gefitinib resistance. Methods CD133+ and CD133- cells were separated from EGFRvIII+ clinical specimens of three patients with newly diagnosed GBM. Then, RT-PCR was performed to evaluate EGFRvIII and EGFR expression in CD133+ and CD133- cells. The tumorigenicity and stemness of CD133+ cells was verified by intracranial implantation of 5x103 cells into immunodeficient NOD/SCID mice. Finally, cells were evaluated for their sensitivity to EGFR tyrosine kinase inhibition by gefitinib. Results RT-PCR results showed that the sorted CD133+ cells expressed EGFRvIII exclusively, while the CD133- cells expressed both EGFRvIII and EGFR. At 6-8weeks postimplantation, CD133+/EGFRvIII+/EGFR- cells formed intracranial tumors. Cell counting kit-8 results showed that the IC50 values of the three isolated EGFRvIII+ cell lines treated with gefitinib were 14.44, 16.00, and 14.66M, respectively, whereas the IC50 value of an isolated EGFRvIII- cell line was 8.57M. Conclusions EGFRvIII contributes to the stemness of cancer stem cells through coexpression with CD133 in GBMs. Furthermore, CD133+/EGFRvIII+/EGFR- cells have the ability to initiate tumor formation and may contribute to gefitinib resistance.

语种: 英语
所属项目编号: 81272790
项目资助者: National Natural Science Foundation of China ; Foundation of National Science and Technology Major Project Focusing on Drug Innovation from The Ministry of Science and Technology of the People&prime ; s Republic of China
WOS记录号: WOS:000320197500004
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/60227
Appears in Collections:基础医学院_细胞生物学系_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.PLA China, Navy Gen Hosp, Beijing, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Dept Cell Biol, Beijing 100871, Peoples R China
3.Beijing Union Med Coll Hosp, Beijing, Peoples R China
4.Beijing PLA, Mil Gen Hosp, Affiliated Bayi Brain Hosp, Beijing, Peoples R China
5.Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100871, Peoples R China
6.Peoples Liberat Army Gen Hosp, Dept Nucl Med, Beijing, Peoples R China
7.Peking Univ, Med & Hlth Anal Ctr, Beijing 100871, Peoples R China

Recommended Citation:
Liu, Xu-Jie,Wu, Wen-Tao,Wu, Wei-Hua,et al. A Minority Subpopulation of CD133+/EGFRvIII+/EGFR- Cells Acquires Stemness and Contributes to Gefitinib Resistance[J]. CNS NEUROSCIENCE & THERAPEUTICS,2013,19(7):494-502.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Liu, Xu-Jie]'s Articles
[Wu, Wen-Tao]'s Articles
[Wu, Wei-Hua]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Liu, Xu-Jie]‘s Articles
[Wu, Wen-Tao]‘s Articles
[Wu, Wei-Hua]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace